FACTSHEET

ACHIEVING A SUSTAINABLE HEALTH EQUITYBiocon Biologics is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. Building on the four pillars of Patients, People, Partners and Business, the Company is developing, manufacturing and commercializing, along with its partners, a range of high-quality, safe and e�ective biosimilars that o�er a�ordable alternatives to expensive biologic medicines. Its cutting-edge R&D and global scale manufacturing have provided an innovative and robust pipeline of biosimilar molecules across. Five of these are commercialized in several global markets with some of them being marketed in developed markets of US, Europe, Australia, Canada and Japan. The Company aspires to benefit several million patient lives with its biosimilars.

Biocon Biologics is a subsidiary of Biocon Ltd. (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013)

*Status Mar 2021 **Key regulatory approvals from US, EU, Japan, Canada, Australia, Brazil, Mexico, Turkey, GCC etc.

FULLY INTEGRATED BIOSIMILARS PLAYER

2Development Partnerships(Viatris, Sandoz)

939Registered Trademarks*

5Products taken fromLab to Market

~950Patents granted (Biologics)*

4800+High-quality, diverse talent pool

2R&D sites (Bengaluru, Chennai)

3Manufacturing sites(2 Bengaluru, 1 Malaysia)

USD 330Million raised through PE investments till date

25+cGMP approvals fromInternational regulatory agencies**

INNOVATION

• Creating a culture of constant innovation where everyone is motivated to contribute their slice of genius

• Leveraging cutting-edge science, innovative tech platforms, design thinking and advanced R&D capabilities

PURPOSE

• Lowering treatment costs while ensuring better patient care and improved healthcare outcomes

• Be a global leader in delivering high-quality and low-cost biosimilars across the globe

WORLD CLASS RESEARCH TALENT AND INFRASTRUCTURE

85,000sq. ft. state-of-the-art research facility in Bengaluru

8,000sq. ft. microbial and cell culture pilot plants

60,000sq. ft. research center in Chennai

45,000sq. ft. plan in Malaysia

4,800+employees

15%with MDs or PhD's

70%with Master's degrees

Alumnifrom leading Indian and International universities

FACILITIES

TALENT

*Number of lives is calculated based on volume supplied#Partner Viatris has in-licensed product, Biocon Biologics continues to have economic benefit

2.25+billion doses of biosimilar insulins provided for patients globally so far

8

3.1+million* patients served globally through our biosimilars till date

PATIENT CENTRIC INNOVATIVEHEALTHCARE SOLUTIONS

State-of-the-art manufacturing facilities - mammalian & microbial

Facilities conform to most stringent cGMP guidelines

Regulatory approvals - EMA, US FDA, Health Canada, ANVISA, COFEPRIS, PMDA, TGA, MCC etc.

New sterile injectables facility commercialized in FY20

New state-of-the-art monoclonal antibodies facility commissioned in FY20

GLOBAL SCALE MANUFACTURING EXPERTISE

SEVERAL FIRSTS TO OUR CREDIT IN THE AREA OF BIOSIMILARS

company globally to get U.S. FDA approval for biosimilar Trastuzumab (2017)

company from India to have a biosimilar approved in the U.S.: Trastuzumab (2017)

company to get U.S. FDA approval for biosimilar Pegfilgrastim (2018)

company from India to have a biosimilar commercialized in U.S.: Pegfilgrastim (2018)

company to get approval for and launch biosimilar Trastuzumab in Australia, Canada (2019)

to make biosimilar Insulin Glargine available on Australia's Pharmaceutical Benefits Scheme (PBS)

1st

1st1st1st

1st

1st

biosimilars approved so far: Trastuzumab, Pegfilgrastim, Bevacizumab, Adalimumab#, rh-Insulin, Insulin Glargine, Etanercept, Insulin Aspart#.

Committed to universal access to rh-insulin by reducing prices for low and middle-income countries (LMIC) to less than 10 US cents/day

rh-Insulin approved in 40+ countries

BIOCON BIOLOGICS IS AMONG THE TOP 5 INSULINS PLAYERS GLOBALLY, VERTICALLY INTEGRATED AND COST COMPETITIVE

Follow us at

Biocon Biologics LimitedBiocon House, Semicon Park, Electronics City, Phase - IIHosur Road, Bengaluru, Karnataka 560100. IndiaTelephone: +91 80 6775 6775Email: corporate.communications@biocon.com | Website: www.biocon.com

01

02

Fact Sheet last updated on 30th April 2021.

BIOCON BIOLOGICS HAS INCREASED ACCESS TO HIGH QUALITY INSULINS IN SEVERAL COUNTRIES

03 Insulin Glargine approved in 60+ countries 04 Independent development program for rh-insulin for the US market

05 In multiple countries like Mexico and Malaysia, nearly all insulin-requiring diabetics take Biocon's Insulin

CommercializedBiosimilars

ApprovedBiosimilars

Adalimumab#Approved in US

Insulin Aspart#Approved in EU

Under-ReviewBiosimilars

Bevacizumab*

U.S.

Insulin Aspart*

U.S.

Adalimumab#

Launched in EU

Etanercept#Launched in EU

Insulin Glargine 100 IU / ml*

Launched in U.S., EU, Australia, Japan^

& selected MoW markets

Recombinant Human InsulinLaunched in India, Malaysia, Mexico

& selected MoW markets

Trastuzumab*

Launched in U.S., EU, Canada, Australia & selected MoW markets

Pegfilgrastim*

Launched in U.S., Canada & Australia

Bevacizumab*Approved in EU

Bevacizumab*

Launched in India & Sri Lanka

MAJOR GLOBAL BIOSIMILARS PLAYER

*Partnered with Viatris#Partner Viatris has in-licensed product, Biocon Biologics continues to have economic benefit^Japan is outside of Viatris partnership